These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33847289)

  • 1. The Impact of Vitamin D on Response to Anti-tumor Necrosis Factor-α Therapy in Children With Inflammatory Bowel Disease.
    Hizarcioglu-Gulsen H; Kaplan JL; Moran CJ; Israel EJ; Lee H; Winter H
    J Pediatr Gastroenterol Nutr; 2021 May; 72(5):e125-e131. PubMed ID: 33847289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-α therapy in inflammatory bowel diseases.
    Zator ZA; Cantu SM; Konijeti GG; Nguyen DD; Sauk J; Yajnik V; Ananthakrishnan AN
    JPEN J Parenter Enteral Nutr; 2014; 38(3):385-91. PubMed ID: 24088707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases.
    Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
    Aliment Pharmacol Ther; 2017 Mar; 45(5):653-659. PubMed ID: 28074487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
    Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
    Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America.
    Kerur B; Fiedler K; Stahl M; Hyams J; Stephens M; Lu Y; Pfefferkorn M; Alkhouri R; Strople J; Kelsen J; Siebold L; Goyal A; Rosh JR; LeLeiko N; Van Limbergen J; Guerrerio AL; Maltz RM; Karam L; Crowley E; Griffiths AM; Heyman MB; Deneau M; Benkov K; Noe J; Moulton D; Pappa H; Galanko J; Snapper S; Muise AM; Kappelman MD; Benchimol EI
    J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):64-69. PubMed ID: 35622080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Relevance of Vitamin D and Antinuclear Antibodies in Patients with Inflammatory Bowel Disease Under Anti-TNF Treatment: A Prospective Study.
    Santos-Antunes J; Nunes AC; Lopes S; Macedo G
    Inflamm Bowel Dis; 2016 May; 22(5):1101-6. PubMed ID: 26818421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Clinical Outcomes in Pediatric Patients with Ileocolonic Crohn Disease Treated with Infliximab Versus Adalimumab.
    Fanous E; Marshanski T; Tal N; Matar M; Weintraub Y; Shamir R; Shouval DS
    J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):358-365. PubMed ID: 37276146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors are associated with vitamin D levels in IBD patients: A retrospective analysis.
    Schäffler H; Schmidt M; Huth A; Reiner J; Glass Ä; Lamprecht G
    J Dig Dis; 2018 Jan; 19(1):24-32. PubMed ID: 29232067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
    Salvador-Martín S; Raposo-Gutiérrez I; Navas-López VM; Gallego-Fernández C; Moreno-Álvarez A; Solar-Boga A; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Fobelo MJ; Millán-Jiménez A; Rodriguez-Martinez A; Vayo CA; Sánchez C; Tolin M; Bossacoma F; Pujol-Muncunill G; González de Caldas R; Loverdos I; Blanca-García JA; Segarra O; Eizaguirre FJ; García-Romero R; Merino-Bohórquez V; Sanjurjo-Sáez M; López-Fernández LA
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases.
    Dalal RS; Ermann J; Carlin A; Mitri J; Allegretti JR
    Clin Rheumatol; 2023 Nov; 42(11):3001-3006. PubMed ID: 37428414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
    Torres P; Cañete F; Núñez L; Aguilar A; Mesonero F; Calafat M; Fernández C; Teniente A; Mañosa M; López-Sanromán A; Domènech E
    Dig Dis Sci; 2020 Jul; 65(7):2036-2043. PubMed ID: 31858325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.